Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT07023601

International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva.

Sentinel Node Biopsy in Relapsed Vulvar Cancer. VULCA-NODE Study.

Status
Enrolling By Invitation
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Hospital Universitario La Paz · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

Acronym: VULCA-NODE Study Title: Sentinel Node Biopsy in Relapsed Vulvar Cancer Primary Objetive: To evaluate the SLN detection rate in the first recurrent vulvar carcinoma setting. Secondary Objetives: * To compare the utility of different tracers in the detection of SLN for recurrent disease and the injection pattern. * To evaluate the surgical complications rate. * To analyze the nodal status by ultrastaging . * To assess the disease free and overall survival at 24 months from the first recurrence, as well as the dissemination pattern after the procedure. Study Design: International prospective multicentre study Inclusion Criteria: * First local recurrent squamous cell carcinoma of the vulva (SCC). * Unifocal, smaller or equal than 4 cm vulvar tumor not involving urethra, vagina or anus. * No distant or groin metastasis. * To be able to understand the study and sign informed consent. * Over 18 years old. * To be able to undergo planned follow up. Exclusion Criteria: * Multifocal recurrent disease of the vulva. * Previous bilateral IFL. * Synchronous, non-curable second malignancy. Timing: 4 years

Conditions

Interventions

TypeNameDescription
OTHERSentinel Lymph Node Biopsy in first local recurrent vulvar carcinomaAll patients will undergo a local tumor radical excision and unilateral (if medial border \> 1 cm from midline) or bilateral (medial border \< or equal to 1 cm from midline) Sentinel Lymph Node procedure, followed by bilateral Inguinophemoral lymphadenectomy. .

Timeline

Start date
2025-08-01
Primary completion
2027-12-31
Completion
2029-12-31
First posted
2025-06-17
Last updated
2025-06-17

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT07023601. Inclusion in this directory is not an endorsement.